Deals Of The Week: Wyeth/Santaris, Novartis/HHS, Cephalon/Ception ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
People In The News – Tracking The Latest Industry Personnel Moves
New top leadership at Pulmatrix, Althea and Mucosis; McKesson names Mark Walchirk president of U.S. pharma business; Former FDA Deputy Commissioner Scott Gottlieb joins Aptiv board. More personnel announcements in this month’s column.
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.
Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash
Formerly legal adversaries, the two companies will co-develop PEG-interferon lambda, currently in Phase Ib for hepatitis C.